SYK Stock Chart & Stats
$5504.00
$120.94(2.10%)
At close: 4:00 PM EDT
$5504.00
$120.94(2.10%)
Day’s Range― - ―
52-Week Range$4,499.55 - $7,207.06
Previous CloseN/A
Volume264.00
Average Volume (3M)195.00
Market Cap
$1.79T
Enterprise Value$133.50K
Total Cash (Recent Filing)$3.48B
Total Debt (Recent Filing)$14.94B
Price to Earnings (P/E)28.3
Beta-0.31
Next Earnings
Oct 29, 2026EPS Estimate
60.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.73
Shares Outstanding383,573,060
10 Day Avg. Volume31
30 Day Avg. Volume195
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6,341.28Price Target Upside15.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)253.69
Revenue Forecast (FY)$460.95B
Bulls Say, Bears Say
Bulls Say
Strong Organic Growth And Expanding MarginsBroad-based organic growth paired with double-digit adjusted EPS expansion indicates strong demand and operating leverage. Higher gross and operating margins can support reinvestment, innovation, and earnings durability, while 2026 guidance preserves a high-single-digit growth outlook.
Robust Free Cash Flow And Improving LeverageStrong cash generation provides internal funding for product development, acquisitions, dividends, and debt management. The simultaneous improvement in leverage strengthens financial flexibility, although disciplined capital allocation remains important as Stryker continues investing for growth.
Sustained Product Innovation And Digital ExpansionFDA authorization and successful clinical use establish a new digital platform for intraoperative workflows, extending Stryker’s offering beyond traditional devices. This can deepen hospital relationships, create future software and system opportunities, and reinforce its innovation-led competitive position.
Bears Say
Peripheral Vascular Supply DisruptionThe disruption demonstrates that operational issues within a key product line can directly reduce sales and delay procedures. Even with management expecting manageable backorders by the end of Q3, recovery timing and lost customer activity may weigh on results over the coming quarters.
Residual Cybersecurity Costs And Production EffectsOngoing remediation and elevated technology spending can pressure earnings even after production resumes, while prior shutdowns created unfavorable cost absorption. The incident therefore remains a business execution burden that may limit margin conversion and earnings consistency in the near term.
Meaningful Absolute Debt ExposureAlthough leverage has improved, the debt balance remains substantial and creates continuing obligations for interest, refinancing, and capital allocation. Higher financing needs from acquisitions or a less favorable rate environment could reduce flexibility to fund growth and shareholder returns.
Stryker News
SYK FAQ
What was Stryker Corporation’s price range in the past 12 months?
Stryker Corporation lowest stock price was $4499.55 and its highest was $7207.06 in the past 12 months.
What is Stryker Corporation’s market cap?
Stryker Corporation’s market cap is $1.79T.
When is Stryker Corporation’s upcoming earnings report date?
Stryker Corporation’s upcoming earnings report date is Oct 29, 2026 which is in 49 days.
How were Stryker Corporation’s earnings last quarter?
Stryker Corporation released its earnings results on Jul 30, 2026. The company reported $62.34 earnings per share for the quarter, beating the consensus estimate of $58.927 by $3.413.
Is Stryker Corporation overvalued?
According to Wall Street analysts Stryker Corporation’s price is currently Undervalued.
Does Stryker Corporation pay dividends?
Stryker Corporation does not currently pay dividends.
What is Stryker Corporation’s EPS estimate?
Stryker Corporation’s EPS estimate is 60.46.
How many shares outstanding does Stryker Corporation have?
Stryker Corporation has 383,573,060 shares outstanding.
What happened to Stryker Corporation’s price movement after its last earnings report?
Stryker Corporation reported an EPS of $62.34 in its last earnings report, beating expectations of $58.927. Following the earnings report the stock price went down -3.45%.
Which hedge fund is a major shareholder of Stryker Corporation?
Currently, no hedge funds are holding shares in MX:SYK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stryker Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6,341.28 (15.21% Upside)
$6,341.28 (15.21% Upside)
Blogger Sentiment
Bullish
MX:SYK Sentiment 67%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $2.0B over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.16%
12-Months-Change
Fundamentals
Return on Equity
1.34%
Trailing 12-Months
Asset Growth
3.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
SYK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad recovery and operational momentum: solid organic growth (9%), a strong adjusted EPS beat (+17.9%), expanding margins, record Mako performance, multiple product launches and healthy cash generation/backlog. Key negatives were an acute supply disruption in peripheral vascular (Inari) that drove a U.S. vascular decline (‑6.7%), lingering costs and absorption effects from the prior cybersecurity incident, and some launch timing variability. Management expects backorders to be manageable by end of Q3 and reiterated confidence in the full‑year outlook and capital demand, so positives materially outweigh manageable near‑term headwinds.View all MX:SYK earnings summariesSYK Net sales Breakdown
62.30% MedSurg and Neurotechnology
37.70% Orthopaedics and Spine

SYK Stock 12 Month Forecast
Average Price Target
$6,341.28
▲(15.21% Upside)
Technical Analysis
Integra Lifesciences
―
Medtronic
―
Smith & Nephew Snats
―
Zimmer Biomet Holdings
―
Globus Medical
―











